BioAim Scientific (Kanada)
The Bioaim Human CD229 ELISA kit is a solid phase sandwich ELISA (enzyme-linked immunosorbent assay) for the quantitative measurement of CD229 in Human serum, plasma and cell culture media. An antibody specific for Human CD229 was coated on a 96-well plate. Standards and samples are added to the wells and any CD229 present binds to the immobilized antibody. The wells are washed and biotinylated anti-Human CD229 antibody is added. After washing away unbound biotinylated antibody, HRP-conjugated streptavidin is added to the wells. The wells are again washed and TMB substrate solution is added, which produces a blue color in direct proportion to the amount of CD229 present in the initial sample. The Stop Solution changes the color from blue to yellow, and the microwell absorbances are read at 450 nm.Research Area cell adhesion;
lymphocyte antigen 9 (CD229) Background: CD229, also known as Ly9 and SLAMF3, is a 120 kDa type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family. CD229 is expressed on T and B cells, thymocytes, and more weakly on NK cells. Homophilic binding between CD229 molecules is mediated by the N-terminal Ig‑like domain. Human and mouse CD229 exhibit cross-species binding. Antigen stimulation of lymphocytes induces CD229 clustering to sites of T cell – B cell contact. Two tyrosines in the cytoplasmic domain are required for association of CD229 with the adaptor proteins AP-2 (μ2 chain) and GRB-2 and both are required for CD229 internalization. In addition, there are two ITSMs which mediate phosphorylation-dependent CD229 association with SAP and SHP-2.
CD229, SLAMF3, hly9, mLY9
Serum, plasma, Cell culture supernatant
|Antigen Name||lymphocyte antigen 9|
|Detection Range||81.9-20000 pg/ml|
|Alias||CD229, SLAMF3, hly9, mLY9|